Additionally, our findings on the therapeutic targeting of miR-208a, which modulates ZEB2 expression, offer further avenues for exploring potential interventions to enhance cardiac function and mitigate hypertrophic responses in IHD (Figure 7). This evidence concerns the gene ZEB2 and myocardial ischemia.